Form Health and Lilly Tackle Employer Obesity Drug Dilemma

BOSTON, MA – March 13, 2026 – As companies across the United States face a mounting financial crisis fueled by the high cost of new obesity medications, a strategic collaboration aims to offer a path forward. Form Health, a virtual obesity medicine clinic, announced it has joined Eli Lilly and Company's Lilly Employer Connect platform, a move designed to provide employers with more predictable pricing and expanded access to sought-after GLP-1 drugs.

This partnership lands in the middle of a fierce debate within corporate benefits departments, which are struggling to balance employee demand for effective weight-loss treatments with budget-breaking pharmaceutical costs. By integrating Form Health's physician-led care model with Lilly's direct-to-employer pricing structure, the collaboration seeks to create a more sustainable framework for managing one of the costliest chronic diseases in the nation.

The Employer's Billion-Dollar Dilemma

Obesity has become a staggering economic burden for American businesses. In 2023 alone, obesity and excess weight cost U.S. employers an estimated $425.5 billion in medical expenses, disability, workers' compensation, and lost productivity. With over 100 million American adults living with obesity, employers are on the front lines, and the advent of highly effective GLP-1 medications like Eli Lilly’s Zepbound has presented both a powerful tool and a profound financial challenge.

These drugs, while clinically effective, carry list prices often exceeding $1,000 per month, translating to an annual cost of $8,000 to $10,000 per employee. For some companies, GLP-1s now account for over 15% of their total annual healthcare claims, contributing to projections of a 9.5% rise in overall employer healthcare costs in 2026. This has led to inconsistent coverage; while larger firms are more likely to cover these medications for weight loss, less than a quarter of all employers with 200 or more workers currently do, leaving a significant access gap.

"Employers continue to tell us they want to better support their employees' health but face real challenges in providing coverage for obesity management medicines," said Kevin Hern, Senior Vice President of Lilly Employer at Lilly USA, in a statement. The complexity of traditional pharmacy benefit manager (PBM) contracts often adds another layer of opaque pricing, making it nearly impossible for companies to forecast expenses accurately.

A New Playbook: Pharma's Direct Line to Employers

In response to this market friction, Eli Lilly has engineered a disruptive strategy with its Lilly Employer Connect platform. Launched in March 2026, the platform circumvents the traditional PBM model by creating a direct pathway for employers to access medications at a transparent, fixed price. Through the program, Lilly offers its GLP-1 medication, Zepbound, at a discounted rate of $449 for all doses.

This approach gives employers unprecedented cost predictability. The platform features a network of over 15 independent program administrators—including telehealth providers like Teladoc Health, digital health companies like Calibrate, and even Mark Cuban's Cost Plus Drug Company—allowing employers to design a benefits solution that fits their specific needs. Form Health is the latest high-profile specialist to join this growing ecosystem.

"This expanded collaboration reflects the rapid evolution in how employers are approaching obesity care and where the market is heading," said Evan Richardson, Founder & CEO of Form Health. "As demand for effective treatments continues to explode, employers are looking for solutions that combine evidence-based care, responsible prescribing, cost predictability, and measurable outcomes."

Beyond the Pill: The Push for Comprehensive Care

The promise of Lilly's platform is predictable pricing, but the key to long-term success, experts argue, lies in the clinical support wrapped around the prescription. This is where Form Health positions its core value. The company offers what it calls "gold-standard wraparound care" delivered entirely through a virtual clinic model.

This model is built on a foundation of deep clinical expertise. Care is led exclusively by physicians certified by the American Board of Obesity Medicine (ABOM), a specialization held by only about 8,000 doctors nationwide. These physicians are supported by a dedicated care team of advanced practice providers and registered dietitians who work with patients on personalized nutrition, physical activity, and behavioral health changes.

This emphasis on clinical rigor is crucial for ensuring "responsible prescribing." The approach combines a thorough medical assessment with lifestyle interventions, regular monitoring, and patient education—a stark contrast to some direct-to-consumer platforms that have been criticized for prescribing powerful medications with minimal oversight. By using "severity-aware prescribing protocols," Form Health aims to ensure that medications are used appropriately and effectively as part of a holistic, long-term health strategy.

The ROI Equation: Balancing Cost, Adherence, and Health

Form Health's model comes with a bold promise: a guaranteed return on investment (ROI) for its enterprise partners. While the high upfront cost of GLP-1s is daunting, emerging data supports the premise of long-term savings. A January 2026 Aon report analyzing data from over 50 million people found that sustained GLP-1 use reduced medical cost growth by 3% to 7% for weight-loss patients within 18 months.

The logic is that increased pharmacy spending is eventually offset by a reduction in costs associated with obesity-related conditions, such as cardiovascular events, diabetes, and hospitalizations. GLP-1s have been shown to lower the risk of heart attacks and strokes, improving overall cardiometabolic health.

However, the ROI calculation is not simple. Real-world adherence to these injectable drugs is often lower than in clinical trials, with many patients discontinuing use within a year. Furthermore, studies indicate that up to 39% of weight lost on GLP-1s can be lean muscle mass. Without a concurrent focus on strength and function, this could lead to frailty and higher musculoskeletal claims, potentially negating some of the savings. This is why providers like Form Health argue that pairing medication with structured clinical support, including nutrition and exercise guidance, is essential for achieving both positive health outcomes and a true financial return.

By integrating with Lilly Employer Connect, Form Health can offer employers multiple pathways for GLP-1 coverage—from existing PBMs to direct manufacturer programs—all while providing the comprehensive clinical oversight designed to maximize the long-term value of these powerful treatments. This partnership exemplifies a broader market shift toward integrated solutions that address not just the prescription, but the entire ecosystem of chronic disease management, potentially reshaping the future of employee health benefits.